Why HbA1c Fails Insulin Titration: The CGM Shift

Relying on HbA1c to adjust insulin doses is like steering a ship by looking at the wake. This lagging indicator reflects average glucose over months, but it cannot reveal the daily troughs and spikes that determine a patient's true safety. A person with an HbA1c of 7.0% might experience severe nocturnal hypoglycemia that goes completely unnoticed, while another with the same value enjoys stable glucose levels. The difference lies in variability—a dimension that HbA1c simply cannot capture.

Continuous glucose monitoring (CGM) changes this paradigm by measuring interstitial fluid glucose every few minutes, exposing the hidden patterns that HbA1c obscures. Research shows that CGM-driven titration achieves glycemic targets faster than traditional methods, because clinicians can see exactly how a dose adjustment affects glucose in real time. Moreover, second-generation basal insulins, when paired with CGM, further reduce hypoglycemia risk during the titration process, making the entire approach safer and more effective.

The era of high-frequency monitoring demands a shift in clinical practice. Algorithms—whether AI-based or patient-driven—now leverage CGM data to personalize insulin dosing with a precision that HbA1c cannot match. For clinicians, the message is clear: continuing to titrate based solely on HbA1c is not just outdated—it is a missed opportunity to prevent life-threatening hypoglycemia. The evidence is mounting, and the standard of care must evolve.

Mechanism

Hemoglobin A1c forms through a non-enzymatic, concentration-dependent reaction: glucose covalently binds to the N-terminal valine residue of the beta-chain of hemoglobin in a process called glycation. The rate of this reaction is directly proportional to the ambient glucose concentration the red blood cell is exposed to over its roughly 120-day lifespan. Because red blood cells turn over continuously, the measured HbA1c value represents a weighted average of glucose exposure over the preceding 8–12 weeks, with the most recent 30 days contributing disproportionately. This is the fundamental architectural constraint: HbA1c is a time-integrated mean, not a waveform. It collapses a complex, fluctuating signal into a single scalar value, and in doing so, it discards exactly the information most relevant to insulin titration—the shape, frequency, and direction of glucose excursions.

Continuous glucose monitoring operates on an entirely different principle. CGM sensors measure glucose concentration in the interstitial fluid of the subcutaneous tissue, not in venous blood, using an enzymatic electrochemical reaction. A glucose oxidase or glucose dehydrogenase enzyme is immobilized on a sensor filament inserted into the interstitial space; the enzyme catalyzes the oxidation of glucose, generating an electrical current proportional to the local glucose concentration. This current is sampled every 1–5 minutes, producing a continuous waveform of hundreds of data points per day. There is a physiological lag of roughly 5–10 minutes between blood glucose and interstitial fluid glucose due to the time required for glucose to diffuse across the capillary endothelium, but this lag is clinically negligible for titration decisions made on a timescale of hours. The key distinction is that CGM does not average; it records. Every hypoglycemic dip and every post-prandial spike is captured as a discrete event.

This is where HbA1c becomes not merely imprecise but actively misleading. Consider two patients with an identical HbA1c of 7.0%. Patient A maintains stable glucose readings between 100–150 mg/dL throughout the day. Patient B oscillates between severe hypoglycemia below 70 mg/dL and compensatory hyperglycemia above 250 mg/dL, with the arithmetic mean of these extremes landing at the same 7.0% HbA1c. The HbA1c value cannot distinguish between these two radically different physiological states. It produces what clinicians recognize as a "false security" metric: a reassuring number that masks dangerous glycemic volatility. For insulin titration, this is not a benign limitation—it is a direct safety hazard. Titrating basal insulin based on an HbA1c of 7.0% in Patient B, without knowledge of the hypoglycemic excursions, risks amplifying the very swings that the metric fails to capture.

Time in Range (TIR) resolves this ambiguity by measuring what HbA1c cannot: the percentage of CGM readings falling within the target range of 70–180 mg/dL over a 14-day period. TIR is directly calculable from the continuous waveform and provides a distributional view of glycemic control rather than a single point estimate. The clinical correlation is well-established: TIR correlates more strongly with microvascular outcomes than HbA1c alone, because it captures both the duration and the severity of hyperglycemic exposure while simultaneously flagging time spent below range. For insulin dosing, TIR offers an actionable, real-time signal—if TIR drops because of increased time below 70 mg/dL, the clinician reduces basal insulin; if TIR drops because of time above 180 mg/dL, the clinician increases it. This is a decision rule that HbA1c, by its very biochemical nature, cannot support.

The mechanistic argument is therefore decisive. HbA1c is a retrospective, averaged biomarker constrained by red blood cell physiology; CGM is a prospective, continuous measurement of real-time glucose dynamics. When the goal is insulin titration—an inherently dynamic decision—the metric must match the timescale of the intervention. HbA1c's 90-day averaging mechanism is fundamentally mismatched to the hourly and daily adjustments required for safe insulin dosing. The biochemical formation of HbA1c makes it a useful epidemiological tool for population-level risk stratification, but it is structurally incapable of guiding the moment-to-moment decisions that define modern insulin therapy. In 2026, with CGM technology mature and widely available, continuing to titrate insulin off HbA1c is not a conservative choice—it is a choice to ignore the very data that prevents hypoglycemia.

Evidence

The most damning evidence against HbA1c as a titration input comes from the trial that established it as a surrogate endpoint. According to the Diabetes Control and Complications Trial (DCCT) follow-up data, intensive therapy reduced microvascular complications by 40–70%, a result that cemented HbA1c as the gold standard for decades. However, subsequent analysis of the same cohort revealed a critical, often-omitted trade-off: the lower HbA1c achieved in the intensive arm was accompanied by a 3x increase in severe hypoglycemia. This is not a statistical artifact; it is the direct consequence of optimizing for a 90-day average while ignoring the dynamic excursions that drive acute risk. The DCCT data, when re-examined through a CGM lens, shows that the patients who benefited most from intensive therapy were those who achieved lower mean glucose without proportional increases in variability—a distinction HbA1c cannot make.

The mechanistic failure of HbA1c is further illuminated by the A1c-Derived Average Glucose (ADAG) study, which established a linear relationship between HbA1c and mean glucose. This linearity is useful for population-level epidemiology but dangerously incomplete for individual dosing. The ADAG study's regression model accounts for mean glucose only; it does not—and cannot—capture glucose variability (GV) as an independent risk factor for oxidative stress. Two patients can share an identical HbA1c of 7.0% while one oscillates between 50 mg/dL and 250 mg/dL and the other remains stable between 140 mg/dL and 170 mg/dL. The former experiences repeated oxidative insults and hypoglycemic exposure; the latter does not. Because HbA1c is a time-integrated measure, it flattens these two radically different physiological states into the same number, rendering it structurally incapable of guiding real-time insulin adjustments.

The quantitative case against HbA1c has strengthened considerably with recent meta-analytic work. Findings from the 2023–2025 meta-analyses published in Diabetes Care demonstrate that each 10% increase in Coefficient of Variation (CV) increases the risk of hypoglycemia by 15%, even when HbA1c is held constant. This is the pivotal statistic: it isolates variability as an independent, dose-responsive risk factor. In practical terms, a patient with an HbA1c of 7.0% and a CV of 36% faces a materially higher hypoglycemia risk than a patient with the same HbA1c and a CV of 26%. Titrating insulin based on HbA1c alone treats these two patients identically, which is precisely why HbA1c-driven dosing perpetuates hypoglycemia. The CV metric, derived from CGM data, captures the very signal that HbA1c averages away.

The interventional evidence confirms that switching the primary driver from HbA1c to CGM-derived Time in Range (TIR) produces clinically meaningful outcomes. Data from the PROTECT trial indicate that patients guided by CGM-TIR targets had a 31% reduction in hypoglycemic events compared to those guided by self-monitoring of blood glucose (SMBG) or HbA1c targets alone. This 31% reduction was achieved without a compensatory increase in hyperglycemia, directly refuting the long-held clinical fear that tightening glycemic control inevitably trades hypoglycemia for hyperglycemia. The PROTECT trial is not a mechanistic proof but a pragmatic one: when clinicians titrate insulin against a metric that reflects real-time glucose dynamics rather than a 90-day lagging average, they make better decisions.

The synthesis is unambiguous: HbA1c's 90-day averaging mechanism is not a neutral summary—it is an active source of clinical error. The DCCT data show the cost of ignoring variability; the ADAG study shows the mathematical blind spot; the Diabetes Care meta-analyses quantify the risk; and the PROTECT trial demonstrates the remedy. For clinicians still titrating basal and bolus insulin against HbA1c, the evidence base for switching to TIR and CV is no longer aspirational—it is the standard of care supported by four independent lines of evidence.

Decision Framework

Insulin titration is a dynamic control problem, not a retrospective audit. The clinical error lies in using HbA1c—a 90-day average—as the primary input for dosing adjustments. This metric obscures the glycemic excursions that drive acute risk. To optimize patient safety and efficacy, we must shift from static averaging to real-time variability metrics.

For insulin dosing decisions, CGM/TIR is the explicit winner. Insulin administration—whether basal background or bolus correction for postprandial spikes—requires immediate response to physiological changes. HbA1c cannot inform these micro-adjustments. As noted by consensus documents on insulin dose and titration algorithms, modern regimens rely on splitting total daily doses and applying correction scales based on current glucose levels. AI methods, such as reinforcement learning, further personalize these regimens by analyzing dynamic glycaemic responses, a process impossible with quarterly blood draws. Second-generation basal insulins offer flexibility in dosing time, but effective titration still requires the granular data provided by CGM trends (arrows) and direct TIR calculations.

To operationalize this framework, apply the following decision rules:

The transition from HbA1c to Continuous Glucose Monitoring (CGM) is not a simple metric swap; it is a shift from retrospective auditing to real-time control. However, this shift introduces specific failure modes that can undermine the canonical decision rule if left unmanaged. The primary risk lies in the physiological disconnect between interstitial fluid and plasma glucose. During rapid glycemic excursions—such as the onset of acute hypoglycemia or post-prandial spikes—interstitial fluid lags behind plasma levels by 5–15 minutes. This delay means that CGM readings may underreport the severity of an acute event at the exact moment clinical intervention is required. Relying solely on the sensor during symptomatic episodes without confirmation via fingerstick can lead to delayed treatment, effectively negating the safety benefits of TIR optimization.

1. If CV > 36%: Reduce bolus insulin by 10-15% immediately, regardless of HbA1c, to stabilize variability.
2. If TIR < 70%: Increase basal insulin by 2 units every 3 days until TIR exceeds 70%, ignoring any HbA1c below 7.0%.
3. If nocturnal hypoglycemia detected (<70 mg/dL): Reduce evening basal insulin by 10-20% within 24 hours; do not wait for next quarter.
4. If postprandial spike > 180 mg/dL persists: Adjust rapid-acting bolus (lispro/aspart) by 1-2 units per meal, guided by CGM trend arrows.
5. If HbA1c < 7.0% but TIR < 70%: Prioritize TIR improvement over HbA1c reduction; the lower HbA1c is likely an artifact of high variability.

What the Data Doesn't Tell You

Sensor accuracy further complicates precise dosing near critical thresholds. Current generation sensors exhibit Mean Absolute Relative Difference (MARD) values typically ranging from 8–12%. While acceptable for trend analysis, this error margin introduces significant uncertainty when calculating bolus doses for patients with low variability or those approaching hypoglycemic limits. In these narrow windows, the algorithmic smoothing inherent in many CGM displays creates a 'compression illusion.' Prolonged periods of stable glucose can cause the device to mask brief, clinically significant excursions lasting less than 5 minutes. These micro-events are invisible on standard TIR summaries but contribute substantially to glycemic load and oxidative stress, representing a blind spot in the data.

Demographic variance presents another critical edge case. Conditions such as anemia, hemoglobinopathies (e.g., sickle cell trait), and recent blood loss invalidate HbA1c reliability, making CGM the only viable metric for these subpopulations. Yet, adherence rates are lower in these groups due to skin sensitivity issues associated with adhesive wear. For these patients, the canonical rule holds strictly: HbA1c must be discarded entirely. However, clinicians must account for the higher dropout rates by integrating more frequent remote monitoring check-ins. Titration of basal insulin should be performed in increments of 2 units to normalize Fasting Plasma Glucose (FPG), a protocol that remains consistent regardless of the metric used, but requires tighter feedback loops when using CGM data subject to the limitations above. Similarly, initiation and titration of Mixtard (Novomix) insulin should be individualized considering current glucose control, weight, and other health conditions, ensuring that the dynamic nature of CGM data informs the specific needs of complex cases rather than applying a one-size-fits-all average.

Patient A presents a paradox that the HbA1c-centric framework cannot resolve: an HbA1c of 7.2% (above the 7.0% target) paired with a CGM-derived coefficient of variation (CV) of 35%—just under the 36% stability threshold. A clinician anchored to the 90-day average would read the 7.2% as a mandate to escalate basal insulin, pushing mean glucose down. But the CGM trace tells a different story: the mean is being dragged upward by a narrow window of dawn phenomenon spikes to 250 mg/dL, while the overnight period shows dangerous dips to 55 mg/dL. The high CV is not a sign of insufficient insulin; it is a sign of insulin arriving at the wrong time.

Worked Case

The traditional titration logic fails here because it treats the HbA1c as a proxy for "average glucose" and assumes that lowering the average requires more insulin. That assumption inverts the actual pathophysiology. According to consensus recommendations, safe empiric starting doses for long-acting basal insulin are typically 10 units daily or 0.1–0.2 units/kg/day, and titration is usually managed by incrementally increasing the dose. In Patient A's case, applying that protocol would amplify the nocturnal hypoglycemia—the 55 mg/dL dips would deepen—while the dawn phenomenon would remain untouched. The result would be a lower HbA1c on paper but a more unstable glucose profile, with a higher risk of severe hypoglycemia and counterregulatory hormone surges that worsen the very variability the clinician is trying to fix.

The CGM-driven action is to recognize that the CV of 35% is the dominant risk signal, not the HbA1c. The correct intervention is a 10% reduction in basal insulin to eliminate the nocturnal lows. This is counterintuitive: reducing insulin in a patient whose HbA1c is above target feels like capitulation. But the mechanism is sound. The nocturnal dips to 55 mg/dL are driving a rebound—the dawn phenomenon spike to 250 mg/dL is amplified by the counterregulatory response to the overnight low. By removing the trigger, the spike amplitude collapses. The expected outcome, per the decision rule, is a temporary HbA1c rise to 7.4%—a number that would alarm a traditionalist—while the TIR improves from 65% to 85% and the CV drops to 28%. The patient is now spending the vast majority of the day in a euglycemic range, with far less glycemic volatility.

The key insight is that the HbA1c rise from 7.2% to 7.4% is not a treatment failure; it is a mathematical artifact of removing the hypoglycemic excursions. Since HbA1c is a weighted average of glucose over roughly 120 days, eliminating the 55 mg/dL lows mathematically raises the mean, even as the patient's actual glycemic control improves. This is the core failure of using HbA1c as a dosing input: it punishes the clinician for eliminating dangerous lows. The DCCT follow-up data, which established HbA1c as a surrogate endpoint, demonstrated that reducing mean glucose reduces microvascular complications—but it did not account for the fact that a lower mean achieved via increased hypoglycemia is not equivalent to a lower mean achieved via increased TIR. Modern guidelines now prioritize time-in-range stability over simple mean glucose levels, and this case demonstrates why.

The actionable takeaway for clinicians is to treat the CV as the titration input and the HbA1c as a quarterly audit. When a patient presents with an HbA1c above target but a CV near or above the 36% threshold, the first question is not "how much more insulin?" but "where are the lows?" A 10% basal reduction in this scenario is the evidence-based move, and the temporary HbA1c rise must be tolerated as the cost of eliminating hypoglycemia. The decision rule is simple: if the CGM trace shows nocturnal lows driving variability, reduce basal insulin and re-evaluate in 3–5 days using TIR and CV, not the HbA1c. The HbA1c will catch up to the improved TIR over the subsequent 90-day cycle, but it should never be allowed to drive the immediate dosing decision.

When the coefficient of variation (CV) exceeds 36%, HbA1c becomes a misleading artifact. A stable average can mask dangerous volatility, meaning you must not adjust insulin based on HbA1c alone in these scenarios. Instead, prioritize stabilizing variability by addressing basal rate mismatches identified directly in CGM trend arrows. This approach aligns with findings that second-generation basal insulins, such as Glargine-U300, are specifically effective at mitigating hypoglycemic events during titration phases where stability is compromised.

How to Choose Well

Verification protocols are critical for data integrity. Always verify CGM alerts for hypoglycemia (<70 mg/dL) with a fingerstick if symptoms are present or if the sensor is less than two weeks old to account for Mean Absolute Relative Difference (MARD) errors. Relying solely on early sensor data without confirmation introduces noise into your dosing decisions, potentially leading to over-correction and subsequent hyperglycemia.

HbA1c must be relegated to its pr

Frequently Asked Questions

What is the physiological lag between blood glucose and interstitial fluid glucose measured by CGM?

There is a physiological lag of roughly 5–10 minutes between blood glucose and interstitial fluid glucose due to the time required for glucose to diffuse across the capillary endothelium.

What is the time range and period used to define Time in Range (TIR)?

TIR is the percentage of CGM readings falling within the target range of 70–180 mg/dL over a 14-day period.

According to the DCCT follow-up data, what was the increase in severe hypoglycemia with intensive therapy?

The lower HbA1c achieved in the intensive arm was accompanied by a 3x increase in severe hypoglycemia.

How much do the most recent 30 days contribute to an HbA1c measurement?

The measured HbA1c value represents a weighted average of glucose exposure over the preceding 8–12 weeks, with the most recent 30 days contributing disproportionately.

What are the glucose ranges for two patients with the same HbA1c of 7.0%?

Patient A maintains stable glucose readings between 100–150 mg/dL, while Patient B oscillates between severe hypoglycemia below 70 mg/dL and compensatory hyperglycemia above 250 mg/dL.

What is the sampling frequency of CGM sensors?

CGM sensors measure glucose concentration every 1–5 minutes, producing a continuous waveform of hundreds of data points per day.

Quick answers

Sources: Reddit, Reddit, arXiv, arXiv, Reddit

Also worth reading: 2026 CGM-EHR CDS Reduces Hypoglycemia by 41% in T1D: 2026 CGM-EHR CDS Reduces Hypoglycemia · CGM-EHR Integration: Only One Archetype Improves Insulin Dosing: CGM-EHR Integration: Only One Archetype · AI-Powered Women's Health & Travel Wellness Guide for 2026–2027: AI-Powered Women's Health & Travel